Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: out_of_the_loop who wrote (2448)	7/21/1999 12:40:00 AM
From: Mad2	Respond to of 10293

Howard it's still 1 in 20. Consumer marketing is a investiment and isn't free. Your naive in your thinking. Howard you may be a physican, respectfully however your out of you element when it comes to the business side. Don't forget GUMM = 60% of Gel Tech. Mad2

To: out_of_the_loop who wrote (2448)	7/21/1999 12:42:00 AM
From: DanZ	Respond to of 10293

FWIW, I spoke to Brown Russell at GumTech last week to see if the company foresees any cash flow problems due to the production of Zicam. He said emphatically no, that they have sufficient cash flow to fully supply the pipeline (up to ~50,000 stores) and to meet expected demand after the pipeline is filled. The biggest concern is advertising expense, not production costs. As Howard pointed out, publication in a medical journal accompanied by free PR will mitigate advertising costs to a great extent. Quigley's sales of Cold Eeze increased from $1 million to $70 million in the year after their study was published in the Annals of Internal Medicine. This was due entirely to the free press that they received. I bring up Quigley only to show how publication in a medical journal can affect sales and not to compare Cold Eeze to Zicam. Best of luck to everyone, Dan